公开(公告)号：US11505576B2

公开(公告)日：2022-11-22

申请号：US16977625

申请日：2019-03-12

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Elin Gunneriusson ,  Sophia Hober ,  Sarah Lindbo

IPC: C07K14/00 ,  C07K1/14 ,  C12N15/10

Abstract: The disclosure provides a population of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence Xsc1AELDXsc2Xsc3GVG AXXIKXIXsc4XA XXVEXVQXXK QXILAX. The disclosure also provides methods for selecting and identifying polypeptides from the population, as well as such polypeptides themselves.

公开(公告)号：US20220169712A1

公开(公告)日：2022-06-02

申请号：US17670565

申请日：2022-02-14

Applicant: AFFIBODY AB

Inventor： Nina Herne

IPC: C07K16/18 ,  A61K47/64 ,  C07K14/315 ,  C07K14/47 ,  C07K14/535 ,  C07K14/555 ,  C07K14/575 ,  C07K14/61 ,  C07K14/755

Abstract: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.

公开(公告)号：US20200291102A1

公开(公告)日：2020-09-17

申请号：US16859102

申请日：2020-04-27

Applicant: AFFIBODY AB

Inventor： Nina Herne

IPC: C07K16/18 ,  A61K47/64 ,  C07K14/315 ,  C07K14/47 ,  C07K14/535 ,  C07K14/555 ,  C07K14/575 ,  C07K14/61 ,  C07K14/755

Abstract: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.

公开(公告)号：US20190284241A1

公开(公告)日：2019-09-19

申请号：US16377722

申请日：2019-04-08

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Caroline Ekblad ,  Elin Gunneriusson ,  Torbjörn Gräslund ,  Johan Seijsing ,  John Löfblom ,  Malin Lindborg ,  Fredrik Frejd ,  Lindvi Gudmundsdotter

IPC: C07K14/00 ,  C07K14/735 ,  C07K14/74 ,  C07K14/31

Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US20180305437A1

公开(公告)日：2018-10-25

申请号：US15767801

申请日：2016-10-28

Applicant: AFFIBODY AB

Inventor： Elisabet Wahlberg

IPC: C07K14/705 ,  C07K14/745

CPC classification number: C07K14/70532 ,  A61K38/1774 ,  A61P31/18 ,  A61P31/20 ,  A61P35/02 ,  C07K14/745 ,  C07K2319/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERTX4AX6WEIX10X11LPNLX16X17X18QX20GAFIX25X26LHD. The present disclosure also relates to the use of such a PD-L1 binding polypeptide a prognostic and/or diagnostic agent as well as a therapeutic agent.

公开(公告)号：US20180118807A1

公开(公告)日：2018-05-03

申请号：US15842178

申请日：2017-12-14

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Elin Gunneriusson ,  Malin Lindborg ,  Lars Abrahmsen ,  John Löfblom ,  Torbjörn Gräslund ,  Johan Seijsing

IPC: C07K14/745 ,  C07K14/735 ,  C07K14/31 ,  C07K14/74 ,  C07K14/435 ,  A61K38/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US20170129944A9

公开(公告)日：2017-05-11

申请号：US14159795

申请日：2014-01-21

Applicant: AFFIBODY AB

Inventor： Nina Herne

IPC: C07K16/18 ,  C07K14/47 ,  C07K14/61 ,  C07K14/555 ,  C07K14/755 ,  C07K14/535 ,  C07K14/315 ,  C07K14/575

CPC classification number: C07K16/18 ,  A61K47/64 ,  C07K14/315 ,  C07K14/47 ,  C07K14/4726 ,  C07K14/535 ,  C07K14/555 ,  C07K14/575 ,  C07K14/61 ,  C07K14/755

Abstract: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.

公开(公告)号：US20160200772A1

公开(公告)日：2016-07-14

申请号：US14911319

申请日：2014-08-28

Applicant: AFFIBODY AB

Inventor： Erik Nordling ,  Joakim Nilsson ,  Patrik Strömberg

IPC: C07K14/00 ,  C12Q1/68 ,  G01N33/68

CPC classification number: C07K14/001 ,  C07K1/047 ,  C07K14/31 ,  C07K2319/00 ,  C12Q1/6874 ,  G01N33/6845

Abstract: The present disclosure relates to a class of engineered polypeptides and provides a polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21 AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55). The present disclosure also relates to populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the amino acid sequence EX2X3X4AX6X7EIX10 X11 LPNLX16X17X18QX20 X21 AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55), and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population.

Abstract translation: 本公开涉及一类工程改造的多肽，并提供包含序列EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q（SEQ ID NO：55）的多肽。 本公开还涉及基于共同支架的多肽变体群体，包含氨基酸序列EX2X3X4AX6X7EIX10 X11LPLL16X17X18QX20X21AFIX25X26LX28X29X30PX32QSX35X36LL339E AKKLX45X46X47Q（SEQ ID NO：55）的群体中的每个多肽，以及选择具有 对来自所述群体的预定目标的亲和力。

公开(公告)号：US20150158916A1

公开(公告)日：2015-06-11

申请号：US14551931

申请日：2014-11-24

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Andreas Jonsson ,  Jakob Dogan ,  Per-Åke Nygren

IPC: C07K14/00 ,  C07K16/18 ,  C07K14/535 ,  C07K14/755 ,  C07K14/605 ,  C07K14/61

CPC classification number: C07K14/00 ,  A61K38/00 ,  C07K14/31 ,  C07K14/315 ,  C07K14/535 ,  C07K14/605 ,  C07K14/61 ,  C07K14/755 ,  C07K16/18 ,  C07K2319/00 ,  C07K2319/70

Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.

Abstract translation: 本发明涉及一类对白蛋白具有结合亲和性的工程化多肽。 它还涉及利用这些和其它化合物在不同背景下结合白蛋白的新方法和用途，其中一些对于包括人在内的哺乳动物的疾病的治疗具有重要意义。

公开(公告)号：US08883120B2

公开(公告)日：2014-11-11

申请号：US13928522

申请日：2013-06-27

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Nina Herne ,  Joachim Feldwisch ,  Christofer Lendel ,  Vladimir Tolmachev

IPC: A61K51/08 ,  A61K38/00

CPC classification number: A61K51/08 ,  A61K38/00 ,  A61K51/088 ,  C07K16/32

Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2. Nucleic acids encoding the polypeptides, expression vectors comprising the nucleic acids and host cells comprising the expression vectors are also disclosed.

Abstract translation: HER2结合多肽包含氨基酸序列EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ，其中位置2中的X1是M，I或L，而位置39的X2是S或C（SEQ ID NO：1）。 此外，公开了包含螯合环境的这些肽。 还公开了由包含螯合环境和放射性核素的肽形成的放射性标记的多肽。 此外，具有或怀疑具有HER2过表达的哺乳动物受试者的身体的体内成像方法包括施用这种放射性标记的多肽，然后使用医学成像仪获得身体的图像，以及方法 公开了治疗这种癌症的方法。 此外，这种放射性标记的多肽在诊断和治疗HER2过表达的癌症中的应用。 还公开了编码多肽的核酸，包含核酸的表达载体和包含表达载体的宿主细胞。